Monoclonal antibody drug superior to chemotherapy for advanced acute lymphoblastic leukemia
(University of Texas M. D. Anderson Cancer Center) A Phase III clinical trial involving 101 centers in 21 countries revealed the monoclonal antibody blinatumomab to be more effective than standard chemotherapy for treatment of advanced acute lymphoblastic leukemia (ALL). Study findings were published in the March 1 online issue of the New England Journal of Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 1, 2017 Category: Cancer & Oncology Source Type: news
Genetically engineered T-cells treat leukemia in babies
[Image courtesy of Caroline Davis2010, per Creative Commons 2.0 license]Researchers in London have successfully treated leukemia in two babies, in what they are touting as the world’s first treatment of cancer using genetically engineered immune cells from donors.
Two British infants, who were 11 and 16 months old, were treated using Cellectis’ CAR T-cell product, UCART19, which is an allogeneic CAR T-cell product candidate for the treatment of chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL). They had gone through previous radiation treatments that failed before being treated with Cellectis’...
Source: Mass Device - February 17, 2017 Category: Medical Equipment Authors: Danielle Kirsh Tags: Biotech Research & Development immunotherapy leukemia Source Type: news
Site of care may partly explain survival difference between kids and AYAs with leukemia
(American Association for Cancer Research) Adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) who were not treated at specialized cancer centers had significantly worse five-year survival compared with children with these cancers who were treated at specialized cancer centers, whereas AYAs treated at specialized cancer centers had outcomes comparable to children treated at specialized cancer centers. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 16, 2017 Category: Cancer & Oncology Source Type: news
Amgen Submits Supplemental Biologics License Application For BLINCYTO ® (Blinatumomab) In Relapsed Or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Application Includes Overall Survival Data From Phase 3 TOWER Study to Support Conversion From Accelerated Approval to Full Approval
Additional Data Support Treatment of Patients With Philadelphia Chromosome-Positive Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
BLINCYTO is the First Approved Bispecific CD19-Directed CD3 T Cell Engager (BiTE®) Antibody and First Immunotherapy to Demonstrate Overall Survival Benefit Versus Standard of Care Chemotherapy
THOUSAND OAKS, Calif., Feb. 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental Biologics License A...
Source: Amgen News Release - February 14, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
